JAK2 and acquired polycythemia vera: In particular, JAK2 mutation is invariably present in all patients with polycythemia vera, and observation of the characteristic bone marrow morphology of pan-myelosis would obviate the need for measurement of measurement of red cell mass[1]; however, such an invasive test is likely not justified as a patient screening tool.